All right, thank you. And then just one last one for me and then I'll hop back into the queue. So over the last couple of months, we have seen some activity from Mesoblast in HLHS, specifically some FDA designations in the publication back in December. So could you just, I guess, give us an idea of how the drugs stack up beyond Lomecel-B, obviously, being in a more advanced stage. Specifically, I guess, if there are any key differences in the signaling profiles that might provide a competitive advantage. An ...